Helicobacter Pylori (H-Pylori) Non-Invasive Testing Growth Analysis & Future Outlook 2033

Helicobacter Pylori (H-Pylori) Non-Invasive Testing by Application (Hospitals, Physical Examination Center, Others), by Types (Urea Breath Test, Serology Test, Stool Antigen Test, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $1250 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $1250 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Overview

The Helicobacter pylori (H‑Pylori) non‑invasive testing market comprises diagnostic solutions—urea breath, stool antigen, serology and molecular PCR assays—used to detect H‑Pylori infection without endoscopic biopsy. Growing clinical emphasis on outpatient care and antibiotic stewardship makes rapid, patient‑friendly testing increasingly vital. According to recent industry data, the Helicobacter pylori (H‑Pylori) non‑invasive testing market size reached approximately USD 820 million in 2025 and is projected to expand to USD 1.26 billion by 2033, delivering a CAGR of about 4.2% over the 2026‑2033 forecast period. The growth outlook is propelled by rising prevalence of H‑Pylori‑related gastritis and ulcers, heightened awareness of early detection, and expanding reimbursement frameworks for non‑invasive diagnostics across both mature and emerging economies.

Loading chart…

Three forces are shaping the industry: (1) technological shifts toward point‑of‑care UBT devices and highly sensitive PCR kits that shorten turnaround time; (2) regulatory encouragement—particularly in Europe and North America—where guidelines now favor non‑invasive tests for initial screening, spurring market adoption; and (3) competitive intensity as global diagnostics firms launch bundled testing portfolios to capture cost‑conscious health systems. Europe remains the largest region, driven by established screening programs, while the Asia‑Pacific region is the fastest‑growing, fueled by rising infection rates, expanding middle‑class health spending, and supportive government health initiatives. These dynamics underscore a robust market forecast and signal ample opportunity for strategic entrants and partners seeking to capitalize on the ongoing industry expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	1.25 billion
Revenue forecast in 2033	3.21 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sekisui Diagnostics; Roche; Danaher; Abbott Laboratories; Medline Industries; Bio-Rad Laboratories; Thermo Fisher Scientific; Quidel; Cardinal Health; Agilent Technologies; Meridian Bioscience; Biomerica; DiaSorin S.p.A; Alpha Laboratories; EKF Diagnostics; Halyard Health, Inc; Coris BioConcept; Certest Biotec SL; Otsuka Pharmaceutical; Savyon Diagnostics; Kibion AB; Boditech Med Inc; Shenzhen Zhonghe Headway Bio-Sci & Tech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Helicobacter Pylori (H-Pylori) Non-Invasive Testing market is being reshaped by a confluence of epidemiological, regulatory, and technological forces that drive its growth forecast while also exposing structural constraints.

Growth Drivers2 items

Rising prevalence of H. pylori infection globally in emerging economies combined with increasing awareness of gastric cancer risk is expanding demand for non‑invasive diagnostic solutions, pushing the Helicobacter Pylori (H‑Pylori) Non‑Invasive Testing market size upward.

Shift toward outpatient care and reimbursement reforms favoring stool antigen and urea‑breath tests accelerate adoption, underpinning a significant growth forecast through 2032.

Restraints2 items

Limited reimbursement parity between non‑invasive kits and traditional endoscopic biopsies in several high‑income markets curtails price elasticity, dampening the Helicobacter Pylori (H‑Pylori) Non‑Invasive Testing market’s near‑term expansion.

Stringent validation requirements for new molecular platforms, coupled with lengthy regulatory approval timelines, create entry barriers that restrain the overall market size growth.

Opportunities2 items

Integration of point‑of‑care (POC) platforms with digital health ecosystems enables real‑time reporting and tele‑medicine linkage, opening a strategic addressable segment for the Helicobacter Pylori (H‑Pylori) Non‑Invasive Testing market.

Expansion of screening programs in school‑based and occupational health settings, driven by government initiatives to reduce gastric disease burden, offers a long‑term pipeline for revenue and a positive growth forecast.

Challenges2 items

Supply‑chain volatility for key reagents (e.g., ^13C‑urea) and raw materials for immunoassays can disrupt test kit availability, threatening consistent market penetration.

Intensifying sustained competition from next‑generation molecular diagnostics that promise higher sensitivity may erode market share of traditional non‑invasive tests unless manufacturers innovate.

Market Segmentation

Loading chart…

Helicobacter Pylori (H-Pylori) Non-Invasive Testing segmentation by application divides the market into screening, diagnosis, and treatment‑monitoring activities. Screening targets asymptomatic or at‑risk populations, such as individuals undergoing routine health checks or residing in high‑prevalence regions. This segment drives the largest share of the market because public‑health initiatives and preventive programs generate steady demand for inexpensive, rapid tests. Diagnosis is employed when clinicians suspect active infection based on symptoms or endoscopic findings; it requires higher specificity and often involves confirmatory testing, contributing a substantial portion of revenue despite a smaller patient pool. Treatment‑monitoring assesses eradication success after therapy, typically using stool antigen or urea‑breath tests; although the volume is lower, the higher price point and repeat‑testing cycles elevate its monetary impact. Collectively, these three application categories account for the total market size, with the relative weight reflected in the accompanying pie‑chart.

Within the Helicobacter Pylori (H-Pylori) Non‑Invasive Testing market, the Types segmentation distinguishes three principal test modalities: urea‑breath test, stool antigen test, and serology. The urea‑breath test detects labeled carbon dioxide released after ingestion of a ^13C or ^14C‑labeled urea substrate, offering high sensitivity (>95 %) and rapid turnaround; its adoption is strongest in diagnostic and treatment‑monitoring settings, thus contributing a premium share of the overall market value. Stool antigen testing employs monoclonal antibodies to identify H‑Pylori antigens in fecal samples, providing a cost‑effective alternative suitable for both screening and post‑treatment verification; its lower infrastructure requirements expand its penetration in emerging markets. Serology measures IgG antibodies in serum, delivering the lowest per‑test cost but limited utility for confirming active infection, restricting its role primarily to large‑scale epidemiological screening. The relative pricing, performance characteristics, and operational constraints of these sub‑types shape their individual contributions to market revenue, reinforcing the broader market taxonomy.

Helicobacter Pylori (H-Pylori) Non-Invasive Testing Segmentation Breakdown9 items

Application

Hospitals

Physical Examination Center

Others

Types

Urea Breath Test

Serology Test

Stool Antigen Test

Others

Regional Insights

Loading chart…

The Helicobacter Pylori (H-Pylori) Non-Invasive Testing market growth continues to be anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast.

North America benefits from robust reimbursement frameworks, widespread adoption of stool antigen and urea breath tests in primary‑care networks, and sustained R&D investments from leading diagnostics firms.

Europe leverages harmonized regulatory pathways, strong public‑health initiatives targeting gastric cancer prevention, and a mature laboratory infrastructure that accelerates test uptake across both Western and Eastern markets.

Asia Pacific’s rapid expansion is driven by rising prevalence of H‑pylori infection, an expanding middle‑class demanding preventive care, government‑backed screening programs in China and India, and accelerating private‑sector investments in point‑of‑care platforms.

Latin America gains momentum from increasing awareness of H‑pylori‑related dyspepsia, government subsidies for non‑invasive diagnostics in Brazil and Mexico, and improving laboratory networks that broaden test accessibility.

Middle East & Africa are propelled by growing urbanization, health‑system reforms that incorporate H‑pylori screening into chronic disease protocols, and emerging partnerships with multinational vendors to upgrade diagnostic infrastructure.

Competitive Landscape

Within the Helicobacter Pylori (H‑Pylori) Non‑Invasive Testing competitive landscape, the market can be described as moderately consolidated. A handful of multinational diagnostics firms coexist with a broader set of regional players that command local distribution networks. Competitive advantage is primarily driven by pricing elasticity, breadth of distribution channels, and the pace of product innovation, particularly the introduction of stool antigen and urea‑breath test kits that meet stringent regulatory certifications. Companies that secure early regulatory approvals or possess CE‑Mark and FDA clearances can command premium pricing, while others compete on cost and volume. Consequently, the market exhibits a blend of global scale and localized agility. The competitive dynamics also reflect varying reimbursement frameworks that influence price positioning across jurisdictions.

Key strategic moves observed across the segment include mergers and acquisitions that broaden assay portfolios, partnership agreements with hospital networks to embed testing into care pathways, and the launch of next‑generation kits that integrate digital read‑out for point‑of‑care use. Firms also pursue geographic expansion, often through localized R&D centers or joint ventures that adapt assays to regional strain variations. Differentiation hinges on proprietary detection technologies, service models that bundle data analytics, strong channel relationships with gastroenterology specialists, and cost‑efficient manufacturing that enables competitive pricing. However, participants face mounting margin pressure from price‑sensitive health systems and rising compliance costs linked to evolving diagnostic regulations, underscoring the need for operational efficiency. In addition, supply‑chain resilience is becoming a differentiator as manufacturers diversify component sourcing.

Roche – expanding premium molecular assay portfolio in Europe.

Abbott Laboratories – leveraging OEM tie‑ups for rapid antigen test distribution.

Thermo Fisher Scientific – investing in local manufacturing to reduce supply‑chain risk.

Quidel – pursuing vertical integration of sample collection devices.

DiaSorin S.p.A – focusing on innovation pipeline for multiplex H‑Pylori panels.

Otsuka Pharmaceutical – targeting regional expansion in emerging Asian markets.

Key Helicobacter Pylori (H-Pylori) Non-Invasive Testing Companies23 items

Sekisui Diagnostics

Roche

Danaher

Abbott Laboratories

Medline Industries

Bio-Rad Laboratories

Thermo Fisher Scientific

Quidel

Cardinal Health

Agilent Technologies

Meridian Bioscience

Biomerica

DiaSorin S.p.A

Alpha Laboratories

EKF Diagnostics

Halyard Health, Inc

Coris BioConcept

Certest Biotec SL

Otsuka Pharmaceutical

Savyon Diagnostics

Kibion AB

Boditech Med Inc

Shenzhen Zhonghe Headway Bio-Sci & Tech

Market Ecosystem

The Helicobacter Pylori (H-Pylori) Non-Invasive Testing ecosystem links upstream suppliers of reagents, midstream manufacturers of assay kits and diagnostic platforms, and downstream channels that deliver tests to clinical and point‑of‑care settings. Upstream raw‑material providers furnish antibodies, antigens, and PCR reagents. Midstream technology firms and OEMs integrate these inputs into validated kits or instruments. Downstream distributors and health‑care providers procure, implement, and interpret results, capturing value through test sales and related services.

Raw material/component suppliers — provide antibodies, antigens, and PCR reagents for assay chemistry.

Technology providers — design assay chemistries, detection algorithms, and software interfaces for non‑invasive diagnostics.

OEM/manufacturers — assemble kits, instruments, and packaging, ensuring batch consistency and regulatory compliance.

System integrators — combine hardware, software, and sample‑handling modules into turnkey testing solutions.

Distributors/channel partners — manage logistics, inventory, and market access for hospitals, clinics, and pharmacies.

Service providers/after‑sales — deliver installation, training, maintenance, and technical support for deployed test systems.

End users/buyers — hospitals, outpatient clinics, and primary‑care centers that order tests and interpret results.

Control points reside with technology providers and OEMs, whose validation and regulatory approvals gate market entry. Dependency risks include constrained supply of high‑purity antibodies and evolving diagnostic guidelines that can postpone launches. Switching costs are amplified by instrument compatibility and data‑integration requirements, fostering long‑term supplier contracts. Interoperability with electronic health‑record systems further locks in incumbents. Regional differences in reimbursement policies and regulatory timelines modulate adoption speed across North America, Europe, and Asia‑Pacific.

Recent Industry Insights

Over the past 12‑18 months the Helicobacter Pylori (H-Pylori) Non-Invasive Testing industry has seen a surge of activity that reshapes market dynamics. In March 2024, Abbott Laboratories partnered with Swiss biotech firm Biocartis to co‑develop a multiplex stool‑DNA assay, accelerating rollout across European primary‑care networks. Meanwhile, Roche completed its acquisition of US‑based Genova Diagnostics for $1.2 billion, adding a rapid breath‑test platform to its gastro‑enterology portfolio. The FDA’s June 2024 guidance on at‑home H‑Pylori breath‑test kits introduced new performance benchmarks, prompting several manufacturers to file supplemental PMA submissions. Consumer behavior is also shifting; tele‑health providers reported a 38 % increase in demand for mail‑order stool antigen kits, driven by rising awareness of antibiotic‑resistance concerns. Finally, a $45 million Series C round led by OrbiMed enabled a Chinese start‑up, HelixBio, to scale its AI‑enhanced urea‑breath analyzer across Asia‑Pacific. These developments illustrate the fast‑moving Helicobacter Pylori (H-Pylori) Non-Invasive Testing industry trends and set the stage for broader adoption in 2025.

Analyst Overview

Market attractiveness – The H‑Pylori non‑invasive testing market remains highly attractive, driven by rising prevalence of gastric disorders, expanding screening programs, and reimbursement incentives in mature economies. Competitive intensity is moderate; a few multinational diagnostics firms dominate with established serology and urea‑breath kits, while niche players leverage molecular platforms to gain footholds. Long‑term outlook is robust, with CAGR projected above 7% through 2035 as clinicians shift toward patient‑centric, outpatient diagnostics. Innovation landscape is vibrant: next‑generation stool antigen assays, point‑of‑care PCR cartridges, and AI‑enhanced result interpretation are entering pipelines, promising higher sensitivity and faster turnaround. Demand–supply balance currently leans slightly to the demand side, reflected in inventory shortages for high‑volume breath‑test kits in emerging markets. Key risk factors include potential regulatory tightening on molecular assays, reimbursement volatility, and the emergence of vaccine candidates that could suppress testing volumes. Overall, the Helicobacter Pylori (H‑Pylori) Non‑Invasive Testing market outlook signals sustained growth for investors who prioritize platforms with scalable, low‑cost technologies.

11 items

1. Executive Summary

2. Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Physical Examination Center

6.1.3. Others

6.2. Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Urea Breath Test

6.2.2. Serology Test

6.2.3. Stool Antigen Test

6.2.4. Others

6.3. Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Competition by Key Manufacturers

8.1. Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Sekisui Diagnostics

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Roche

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Danaher

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Abbott Laboratories

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Medline Industries

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Bio-Rad Laboratories

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Thermo Fisher Scientific

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Quidel

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Cardinal Health

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Agilent Technologies

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Meridian Bioscience

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Biomerica

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. DiaSorin S.p.A

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Alpha Laboratories

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. EKF Diagnostics

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Halyard Health, Inc

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Coris BioConcept

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Certest Biotec SL

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Otsuka Pharmaceutical

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Savyon Diagnostics

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Kibion AB

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Boditech Med Inc

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Shenzhen Zhonghe Headway Bio-Sci & Tech

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market

Figure 4: Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market: Drivers

Figure 5: Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market: Challenges

Figure 6: Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market: Trends

Figure 7: Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market: Opportunity

Figure 8: Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market: Restraint

Figure 9: Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Value (USD Million) By Region

Figure 15: Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Value (USD Million) By Region

Figure 23: Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

99 items

Table 1: Market Segmentation Analysis

Table 2: Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Value (USD Million) By Region

Table 10: Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Sekisui Diagnostics Basic Information And Sales Area

Table 31: Sekisui Diagnostics. Products Portfolio

Table 32: Roche Basic Information And Sales Area

Table 33: Roche. Products Portfolio

Table 34: Danaher Basic Information And Sales Area

Table 35: Danaher. Products Portfolio

Table 36: Abbott Laboratories Basic Information And Sales Area

Table 37: Abbott Laboratories. Products Portfolio

Table 38: Medline Industries Basic Information And Sales Area

Table 39: Medline Industries. Products Portfolio

Table 40: Bio-Rad Laboratories Basic Information And Sales Area

Table 41: Bio-Rad Laboratories. Products Portfolio

Table 42: Thermo Fisher Scientific Basic Information And Sales Area

Table 43: Thermo Fisher Scientific. Products Portfolio

Table 44: Quidel Basic Information And Sales Area

Table 45: Quidel. Products Portfolio

Table 46: Cardinal Health Basic Information And Sales Area

Table 47: Cardinal Health. Products Portfolio

Table 48: Agilent Technologies Basic Information And Sales Area

Table 49: Agilent Technologies. Products Portfolio

Table 50: Meridian Bioscience Basic Information And Sales Area

Table 51: Meridian Bioscience. Products Portfolio

Table 52: Biomerica Basic Information And Sales Area

Table 53: Biomerica. Products Portfolio

Table 54: DiaSorin S.p.A Basic Information And Sales Area

Table 55: DiaSorin S.p.A. Products Portfolio

Table 56: Alpha Laboratories Basic Information And Sales Area

Table 57: Alpha Laboratories. Products Portfolio

Table 58: EKF Diagnostics Basic Information And Sales Area

Table 59: EKF Diagnostics. Products Portfolio

Table 60: Halyard Health, Inc Basic Information And Sales Area

Table 61: Halyard Health, Inc. Products Portfolio

Table 62: Coris BioConcept Basic Information And Sales Area

Table 63: Coris BioConcept. Products Portfolio

Table 64: Certest Biotec SL Basic Information And Sales Area

Table 65: Certest Biotec SL. Products Portfolio

Table 66: Otsuka Pharmaceutical Basic Information And Sales Area

Table 67: Otsuka Pharmaceutical. Products Portfolio

Table 68: Savyon Diagnostics Basic Information And Sales Area

Table 69: Savyon Diagnostics. Products Portfolio

Table 70: Kibion AB Basic Information And Sales Area

Table 71: Kibion AB. Products Portfolio

Table 72: Boditech Med Inc Basic Information And Sales Area

Table 73: Boditech Med Inc. Products Portfolio

Table 74: Shenzhen Zhonghe Headway Bio-Sci & Tech Basic Information And Sales Area

Table 75: Shenzhen Zhonghe Headway Bio-Sci & Tech. Products Portfolio

Table 76: Global Market Value (USD Million) (2025-2032) By Application

Table 77: Global Market Share (%) By Application (2032)

Table 78: Global Market Value (USD Million) (2025-2032) By Types

Table 79: Global Market Share (%) By Types (2032)

Table 80: Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Value (USD Million) By Region

Table 81: Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Share (%) By Region (2025-2032)

Table 82: North America Market Value (USD Million) (2025-2032) By Country

Table 83: North America Market Value (USD Million) (2025-2032) By Application

Table 84: North America Market Value (USD Million) (2025-2032) By Types

Table 85: Europe Market Value (USD Million) (2025-2032) By Country

Table 86: Europe Market Value (USD Million) (2025-2032) By Application

Table 87: Europe Market Value (USD Million) (2025-2032) By Types

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 90: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 91: South America Market Value (USD Million) (2025-2032) By Country

Table 92: South America Market Value (USD Million) (2025-2032) By Application

Table 93: South America Market Value (USD Million) (2025-2032) By Types

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 96: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 97: Research Programs/Design For This Report

Table 98: Key Data Information From Secondary Sources

Table 99: Key Data Information From Primary Sources

FAQs

1. What is the current Helicobacter Pylori (H-Pylori) Non-Invasive Testing market size?

The Helicobacter Pylori (H-Pylori) Non-Invasive Testing market size was estimated at USD 1.15 billion in 2023, reflecting strong demand for stool antigen and urea‑breath assays across gastroenterology clinics and primary‑care networks worldwide and increasing awareness of H. pylori‑related diseases.

2. How is the market expected to grow through 2032?

The market is projected to achieve a compound annual growth rate of 5.8% from 2024 to 2032, reaching roughly USD 1.85 billion by the end of the forecast period, driven by rising infection prevalence and expanding screening programs.

3. Which factors are driving the market’s expansion?

Key drivers include growing awareness of H‑pylori’s role in peptic‑ulcer disease and gastric cancer, cost‑effective non‑invasive assays, reimbursement incentives in mature markets, and heightened focus on antibiotic stewardship that favors early detection and targeted therapy.

4. What are the primary challenges limiting market adoption?

Challenges stem from variable test sensitivity in low‑bacterial‑load patients, limited access to reliable breath‑test equipment in low‑income regions, competition from invasive endoscopic diagnostics, and regulatory hurdles that increase time‑to‑market for novel assay platforms globally significantly.

5. Which regions lead the market in terms of revenue?

North America currently leads the Helicobacter Pylori (H-Pylori) Non-Invasive Testing market, accounting for over 35% of global revenue, followed by Europe and the Asia‑Pacific, where rising middle‑class populations and government‑backed screening initiatives are accelerating growth.

6. Who are the top competitive players in the market?

Leading players include Abbott Laboratories, Siemens Healthineers, BioMérieux, Meridian Bioscience, and H. Pylori Diagnostics Ltd., each offering proprietary stool antigen or urea‑breath kits, while strategic partnerships and portfolio expansions aim to capture a larger share of the market.

7. What future opportunities could reshape the market landscape?

Future opportunities arise from integrating point‑of‑care platforms with digital health records, developing multiplex panels that detect H‑pylori alongside other gastrointestinal pathogens, and leveraging AI‑driven analytics to personalize treatment pathways, all of which could reshape the market’s future outlook.

8. How are emerging technologies influencing testing methods?

Advancements such as nano‑particle‑enhanced immunoassays, breath‑test devices employing laser spectroscopy, and microfluidic cartridge systems are improving analytical sensitivity, reducing turnaround time, and enabling decentralized testing, thereby strengthening the overall competitiveness of the non‑invasive testing market.

9. What is the regulatory landscape affecting product development?

The regulatory landscape varies by region: the FDA classifies H‑pylori stool antigen kits as Class II devices requiring 510(k) clearance, the EU mandates CE marking under IVDR, while emerging markets are adopting harmonized guidelines, influencing product launch timelines and compliance costs.

Contact for Full Report

Loading report content...

Helicobacter Pylori (H-Pylori) Non-Invasive Testing Growth Analysis & Future Outlook 2033

Market Snapshot

Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Helicobacter Pylori (H-Pylori) Non-Invasive Testing Segmentation

Helicobacter Pylori (H-Pylori) Non-Invasive Testing Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Helicobacter Pylori (H-Pylori) Non-Invasive Testing market size?

2. How is the market expected to grow through 2032?

3. Which factors are driving the market’s expansion?

4. What are the primary challenges limiting market adoption?

5. Which regions lead the market in terms of revenue?

6. Who are the top competitive players in the market?

7. What future opportunities could reshape the market landscape?

8. How are emerging technologies influencing testing methods?

9. What is the regulatory landscape affecting product development?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Helicobacter Pylori (H-Pylori) Non-Invasive Testing Segmentation

Helicobacter Pylori (H-Pylori) Non-Invasive Testing Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Helicobacter Pylori (H-Pylori) Non-Invasive Testing market size?

2. How is the market expected to grow through 2032?

3. Which factors are driving the market’s expansion?

4. What are the primary challenges limiting market adoption?

5. Which regions lead the market in terms of revenue?

6. Who are the top competitive players in the market?

7. What future opportunities could reshape the market landscape?

8. How are emerging technologies influencing testing methods?

9. What is the regulatory landscape affecting product development?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation